AstraZeneca’s chief executive has raised concerns that the UK’s stringent healthcare policies could undermine the pharmaceutical industry’s future investment and innovation.

Key issues include the collapsed £450 million vaccine plant expansion, rejection of breakthrough drugs for NHS use, and low drug reimbursement rates.

The firm is considering relocating its stock market listing to the U.S. if conditions do not improve.